Pay in 4 interest-free payments of $5.49 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
The patient received monthly injections for 10 years
General Safety Profile Based on the preclinical dataset and the limited human exposure data: No prominent signal of hepatic, renal, or hematological toxicity at tested doses No prominent cardiovascular safety flag Pregnancy and lactation as with most research compounds, safety not established Long-term effects not characterized What Clinicians Should Actually Tell Patients For patients asking about 5-amino-1MQ, a reasonable response framework: What the compound is: A research-stage small molecule inhibiting NNMT with promising preclinical fat loss data
The perceived energy boost reported by non-deficient individuals is likely attributable to placebo effect
you may find you prefer an alternative technique or treatment that has less risk of side effects
